Standards, options and recommendations (SOR) for the management of neutropenic cancer patients (excluding prolonged neutropenia);Standards, options et recommandations pour la prise en charge des neutropenies courtes

Bulletin du Cancer

Volumn 85, Issue 8, 1998, Pages 695-711

  Biron, Pierre ^a   Fuhrmann, Christine ^a   Escande, Marie Christine ^b   Blanc Vincent, Marie Pierre ^c   Crokaert, Françoise ^d   Béal, Jacqueline ^e   Bussy, Véronique ^f   Lesimple, Thierry ^g   Pottecher, Béatrice ^h   Raveneau, Jacques ⁱ   Senet, Jean Marcel ^j   Viot, Michèle ^k  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT CURIE   (France)

^c FNCLCC   (France)

^d JULES BORDET INSTITUTE   (Belgium)

^e CENTRE OSCAR LAMBRET   (France)

^f INSTITUT JEAN GODINOT   (France)

^g CENTRE EUGÈNE MARQUIS   (France)

^h CENTRE PAUL STRAUSS   (France)

ⁱ CENTRE RENÉ HUGUENIN   (France)

^j CENTRE PAUL PAPIN   (France)

^k CENTRE ANTOINE LACASSAGNE   (France)

more..

Author keywords

Cancer; Chemothera py; Granulocytopenia; Guidelines; Immunocompromised host; Infection; Neoplasms; Neutropenia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CYTOTOXIC AGENT; GLYCOPEPTIDE;

ANTIBIOTIC PROPHYLAXIS; CANCER MORTALITY; CANCER PATIENT; CLINICAL PRACTICE; FEVER; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; IMMUNE DEFICIENCY; INFECTION; LENGTH OF STAY; NEUTROPENIA; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEVER; HUMANS; INFECTION; INFECTION CONTROL; NEUTROPENIA;

EID: 7344224343     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Andremont A, Le NA, Baron S, Tavakoli T, Daniel MF, Tancrede C., et al. Secular trends in morbidity and mortality associated with bloodstream infections in 4 296 patients hospitalized in a cancer referral center between 1975 and 1989. Abstracts of the 34th ICAAC 1994; Session 9: Abstract J8, 10.
2. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ann Intern Med 1993; 119 (7 Pt 1): 584-93.
3. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen. J Antimicrobial Chemother 1995; 36: 185-200.
4. Armstrong D, Young LS, Meyer RD, Blevins AH. Infectious complications of neoplastic disease. Med Clin North Am 1971; 55: 729-45.
5. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 99-136.
6. Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. Br Med J 1996; 312: 338-44.
7. Biron P, Fuhrmann C, Viot M, pour le Cemic. Neutropénies : résultats préliminaires avec le céfépime 2g/j. 2. La Lettre de l'Infectiologue 1995; (Hors série): 11-2.
8. Blanc-Vincent MP. Neutropénies induites par la chimiothérapie anti-cancéreuse. Complications infectieuses et traitements. Étude descriptive de 190 épisodes consécutifs au Centre Léon-Bérard. Thèse de doctorat en pharmacie, Université Claude-Bernard - Faculté de pharmacie - Lyon I; 1993, 207 p.
9. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14: 636-43.
10. Blay JY, Le Cesne A, Blanc-Vincent MP, Fervers B, Latour JF, Philip T. Standards, Options et Recommandations pour l'utilisation des facteurs de croissance hématopoïétique en cancérologie. In: Fédération nationale des centres de lutte contre le cancer. Standards, Options et Recommandations. Cédérom édition no 2, John Libbey Eurotext, Paris, 1998.
11. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteriemia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25-31.
12. Bodey GP, Buckley M, Sathe JS, Freireich EJ. Quantitative relationships between circulating leucocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
13. Bodey GP, Elting L, Jones P, Alvarez ME, Rolston K, Fainstein V. Imipenem/cilastatin therapy of infections in cancer patients. Cancer 1987; 60: 255-62.
14. Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis 1993; 17 (suppl. 2): 378-84.
15. Boogaerts MA. Anti-infective strategies in neutropenia. J Antimicrobial Chemother 1995; 36 (suppl. A): 167-78.
16. Bosseray A, Nicolini F, Brion JP, Michallet M, Hollard D, Stahl JP, et al. Évaluation de trois types d'antibiothérapie empirique chez le patient neutropénique fébrile: imipénème-cilastatine versus ceftazidime plus vancomycine versus ticarcilline plus amikacine plus vancomycine. Pathol Biol Paris 1992; 40: 797-804.
17. Bouffet E, Fuhrmann C, Frappaz D, Couillioud D, Artiges V, Charra C, et al. Once daily antibiotic regimen in paediatric oncology. Arch Dis Child 1994; 70: 484-7.
18. Bussy V, Escande MC, Furhmann C, Boineau F, Blanc-Vincent MP, Béal J. et al. Standards, Options et Recommandations pour une bonne pratique des hémocultures en cancérologie. In: Fédération nationale des centres de lutte contre le cancer. Standards, Options et Recommandations. Cédérom édition no 2, John Libbey Eurotext, Paris 1998.
19. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empitic therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrobial Agents Chemother 1995; 39: 445-52.
20. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents Chemother 1996; 40: 1108-15.
21. Cordonnier C. Critères d'efficacité des antibiotiques chez les patients neutropéniques. Actualités méthodologiques: biostatistique, aspects méthodologiques de l'évaluation des anti-infectieux. Springer Verlag, 1993; 165-75.
22. Cordonnier C, Leverger G, Schlemmer B, Andremont A, Boasson M, Herbrecht R, et al. Stratégie antibiotique dans les épisodes fébriles au cours des neutropénics profondes (inférieures à 500 PNN) et prolongées (supérieures ou égales à 7 jours). Recommandations de la commission d'évaluation du Collège français des hématologistes. Nouv Rev Fr Hematol 1994; 36: 289-91.
23. Deconinck E, Cahn JY. Prise en charge des épisodes neutropéniques postchimiothérapie chez l'adulte. Thérapeutiques 1995; 1: 27-9).
24. Del Favero A, Bucaneve G, Menichetti F. Empiric monotherapy in neutropenia: a realistic goal? Scand J Infect Dis Suppl 1995; 96: 34-7.
25. De Pauw BE, Deresinski SC, Feld R, Lane Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994; 120: 834-44.
26. Donnelly JP, Novakova IR, Raemaekers JM, De Pauw BE. Empiric treatment of localized infections in the febrile neutropenic patient with monotherapy. Leuk Lymphoma 1993; 9: 193-203.
27. Dupont B. Azole antifungal agents: emerging and inherent resistance. Curr Op Infect Dis 1995; 8: 4 24-7.
28. Eggimann P. Particularités de la prise en charge des infections, chez le patient neutropénique. Médecine et Hygiène 1995; 53: 1073-81.
29. Eich G, Cometta A, Glauser MP. Pneumonia in neutropenic patients. 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, March 26-30, 1995; Abstract 41 : 8.
30. The EORTC International Antimicrobial Therapy Project Group: three antibiotic regimens in the treatment of infection in febrile granulocytopenic patient with cancer. J Infect Dis 1978; 137: 14-29.
31. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteriemia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987; 317: 1692-8.
32. Escalante CP, Rubenstein EB, Rolston KV. Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients. Support Care Cancer 1996; 4: 358-63.
33. Fervers B, Bonichon F, Demard F, Héron JH, Mathoulin S, Philip T, Renaud-Salis JL, Toma C, Bey P. Méthodologie de développement des standards, options et recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 1995; 82: 761-7.
34. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165-76.
35. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteriemia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996; 15: 291-6.
36. Gucalp R. Management of the febrile neutropenie patient with cancer. Oncology Huntingt 1991: 5: 137-44, 147.
37. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717.
38. Hathorn JW, Pizzo PA. Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients? J Antimicrobial Chemother 1986; 17 (suppl. A): 41-54.
39. Herbrecht R, Letscher V. Épisodes fébriles du patient neutropénique : quelle stratégie en 1995? Méd Mal Infect 1995; 25 (Spécial): 27-35.
40. Herbrecht R, Blaise D, Espinouse D, Leblond V, Sadoun A, Sauvage C, et al. Isépamicine en dose quotidienne unique plus ceftriaxone versus amikacine plus ceftriaxone dans le traitement des neutropénies fébriles. La Lettre de l'Infectiologue 1996; (Hors série): 31-5.
41. Holdsworth MT, Duncan MH. Health care outcomes case study: febrile neutropenia. Am J Health-Syst Pharm 1995; 52 (suppl. 4): S15-8.
42. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever [published erratum appears in J Infect Dis 1990; 161: 1316] [see comments]. J Infect Dis 1990; 161: 381-96.
43. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young I.S. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl. 1): S206-15.
44. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. General guidelines for the evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. In: Beam RT, Gilbert DN, Kunin CM, ed. European guidelines for the clinical evaluation of anti-infective drug products. European Society of Clinical Microbiology and Infectious Diseases, 1993: 221-7.
45. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Inject Dis 1990; 161 : 397-401.
46. Johnson PR, Lin Yin JA, Tooth JA. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrobial Chemother 1992; 30: 203-14.
47. Karp JE, Merz WG, Dick JD. Management of infections in neutropenic patients: advances in therapy and prevention. Curr Op Infect Dis 1993; 6: 405-11.
48. Kattan J, Droz JP, Culine S, Ribrag V, Boutan-Laroze A, Andremont A. Intérèt de l'association pipéracilline-péfloxacine suivie éventuellement par la vancomycine dans le traitement des neutropénies fébriles au cours des chimiothérapies néphrotoxiques. Bull Cancer 1992; 79: 705-12.
49. Kern WV, Hay B, Kern P, Marre R, Arnold R. A randomised trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrobial Agents Chemother 1994; 38: 465-72.
50. Kibbler CC, Prentice HG, Sage RJ, Hoffbrand AV, Brenner MK, Mannan P, et al. A comparison of double beta-lactam combinations with netilmicin/ureidopenicillin regimens in the empirical therapy of febrile neutropenic patients. J Antimicrobial Chemother 1989; 23: 759-71.
51. Kibbler CC, Prentice HC, Sage RJ, Hoffbrand AV, Brenner MK, Noone P. Do double-beta-lactam combinations prolong neutropenia in patients undergoing chemotherapy or bone marrow transplantation for hematological disease? Antimicrobial Agents Chemother 1989; 33: 503-7.
52. Kibbler CC. Neutropenic infectious: strategies for empirical therapy. J Antimicrobial Chemother 1995; 36: 107-17.
53. Klastersky J. L'antibiothérapie empirique chez les malades granulopéniques. Presse Med 1984; 13: 1067-9.
54. Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988; 24 (Suppl. 1): S35-45.
55. Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer 1993; 29A (suppl. I): S6-10.
56. Klein NC, Cunha BA. The selection and use of cephalosporins: a review. Adv Therapy 1995; 12: 83-99.
57. Kremery V. Emerging fungal infections in cancer patients. J Hosp Infect 1996; 33: 109-17.
58. Lazarus HM, Creger RJ, Gerson SL. Infectious emergencies in oncology patients. Semin Oncol 1989; 16: 543-60.
59. Lesimple T, Béal J, Escande MC, Lion C, Blanc-Vincent MP, Bussy V, et al. Standards, Options et Recommandations pour la prévention, le diagnostic et le traitement des infections liées aux voies veineuses en cancérologie. In: Fédération nationale des centres de lutte contre le cancer. Standards, Options et Recommandations. Cédérom édition no 2, John Libbey Eurotext, Paris 1998.
60. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 1992; 327: 99-106.
61. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-maerophage colony-stimulating factor (1). N Engl J Med 1992; 327: 28-35.
62. Love LJ, Schimpff SS, Schiffer CA, Wiernik PH. Improved prognosis for granucytopenic patients with Gram-negative bacteriemia. Am J Med 1980; 68: 643-8.
63. Martino P, Micozzi A. Controversies in the therapy of fever in neutropenic patients. Curr Op Infect Dis 1995; 8: 415-9.
64. Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli C, Klastersky J, et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrobial Agents Chemother 1991; 35: 873-8.
65. Micozzi A, Nucci M, Venditti M, Gentile G, Girmenia C, Meloni G, et al. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993; 12: 1-8.
66. Miller JA, Butler T, Beveridge RA, Kales AN, Binder RA, Smith LJ, et al. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients. Clin Ther 1993; 15: 486-99.
67. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrobial Chemother 1996; 37: 645-63.
68. Nemunaitis J, Meyers JD, Buckner CD, Shannon Dorcy K, Mori M, Shulman H, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78: 907-13.
69. Norrby SR, Vandercam B, Louie T, Runde V, Norberg B, Anniko M, et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis Suffl 1987; 52: 65-78.
70. Petrilli AS, Melaragno R, Barros KV, Silva AA, Kusano E, Ribeiro RC, et al. Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease. Pediatr Infect Dis J 1993; 12: 916-21.
71. Philport-Howard J. Infections in neutropenic patients. Curr Op Infect Dis 1995; 8: 234-40.
72. Pizzo PA, Robichaud KJ, Wesley R, et al. Lever in pediatric and young adult patients with cancer: prospective study of 1,001 episodes. Medicine Baltimore 1982; 61: 153-65.
73. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-11.
74. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-8.
75. Pizzo PA, Ruhin M, Freifeld A, Walsh TJ. The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 1991; 119: 679-94.
76. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-32.
77. Ramphal R, Bolger M, Oblon DJ, Sherertz RJ, Malone JD, Rand KH, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrobial Agents Chemother 1992; 36: 1062-7.
78. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrobial Agents Chemother 1995; 39: 1-8.
79. Rolston KV, Betkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283-91.
80. Rolston KV. Outpatient management of fever in neutropenic patients. Curr Op Infect Dis 1996; 9: 407-10.
81. Ruhenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C., Manzullo E, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71: 3640-6.
82. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988; 108: 30-5.
83. Rubin M, Walsh T, Butler K, Lee J, Lecciones J, Weinberger M. et al. The febrile neutropenic patient: newer options for empirical therapy. Hamatol Bluttransfus 1990; 33: 531-8.
84. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991; 164: 907-16.
85. Saral R, Ambinder R, Burns W, Angelopulos C, Griffin D, Burke P, et al. Acyclovir prophylaxis against Herpes simplex virus infection in patients with leukemia. Ann Intern Med 1983; 99: 773-6.
86. Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284: 1061-5.
87. Senet JM, Herbrecht R, Blanc-Vincent MP, Béal J, Biron P, Bussy V, et al. Standards, Options et Recommandations pour la prévention, le diagnostic et le traitement des candidoses en cancérologie. In: Fédération nationale des centres de lutte contre le cancer. Standards, Options et Recommandations. Cédérom édition no 2, John Libbey Eurotext, Paris, 1998.
88. Shenep JL. Simplification of empiric therapy for the febrile neutropenic oncology patient. Recent Results in Cancer Research 1993; 132: 67-77.
89. Smail A, Ducroix JP, Lafon B, Bruaire JP, Bailler J. L'infection chez le granulopénique. Sem Hôp Paris 1990; 66: 184-8.
90. Soussy CJ, Leclercq R, Duval J. Activité antibactérienne in vitro des associations pipéracilline/quinolones. Pathol Biol 1988; 36: 357-60.
91. Sultan C., Gouault-Heilmann M, Imbert M. Aide-mémoire d'hématologie. Paris: Médecine-Sciences Flammarion, 1987: 32-3.
92. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148: 2561-8.
93. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-22.
94. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994; 12: 107-14.
95. Verhoef J. Prevention of infections in the neutropenic patient. Clin Infect Dis 1993; 17 (Suppl. 2): S359-67.
96. Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 1995; 31A: 2013-22.
97. Wakefield DS. Understanding the cost of nosocomial infections. In: Wenzell RP, ed. Prevention and control nosocomial infections. Baltimore: Williams & Wilkins, 1993; 21-41.
98. Winston DJ, Barnes RC, Ho WG, Young LS, Champlin RE, Gale RP. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med 1984: 77: 442-50.
99. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RH. Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med 1988; 85: 21-30.
100. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone [see comments]. Ann Intern Med 1991; 115: 849-59.